Skip to main content

Table 5 Association between first breast cancer HR status and subtype-specific CBC, among known BRCA1/2 mutation non-carriers

From: Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population

 

Overall CBC

ER+/PR+ CBC

ER+/PR- CBC

ER-/PR- CBC

N (cases/controls)

RRa (95% CI)

RRb (95% CI)

N (cases/controls)

RRa (95% CI)

RRb (95% CI)

N (cases/controls)

RRa (95% CI)

RRb (95% CI)

N (cases/controls)

RRa (95% CI)

RRb (95% CI)

All women tested for BRCA1/2 mutationsc, tumor status at first diagnosis

 ER status

  Positive

336/745

1.0 (ref.)

1.0 (ref.)

100/179

1.0 (ref.)

1.0 (ref.)

41/66

1.0 (ref.)

1.0 (ref.)

26/114

1.0 (ref.)

1.0 (ref.)

  Negative

193/338

1.4 (1.1, 1.9)

1.2 (0.9, 1.6)

22/82

0.6 (0.3, 1.2)

0.7 (0.3, 1.3)

15/31

0.8 (0.3, 2.0)

0.8 (0.3, 2.0)

56/56

4.6 (2.1, 10.2)

3.8 (1.6, 8.9)

  Other/unknownd

176/315

  

33/44

  

9/30

  

19/32

  

 PR status

  Positive

287/615

1.0 (ref.)

1.0 (ref.)

88/160

1.0 (ref.)

1.0 (ref.)

35/61

1.0 (ref.)

1.0 (ref.)

23/95

1.0 (ref.)

1.0 (ref.)

  Negative

172/318

1.3 (1.0, 1.7)

1.1 (0.8, 1.5)

26/86

0.8 (0.4, 1.5)

0.8 (0.5, 1.5)

16/20

2.2 (0.7, 6.8)

2.2 (0.7, 6.8)

56/55

5.3 (2.3, 12.2)

6.8 (2.6, 17.6)

  Other/unknownd

246/465

  

41/59

  

14/46

  

22/52

  

 Joint ER/PR status

  ER+/PR+

250/536

1.0 (ref.)

1.0 (ref.)

84/143

1.0 (ref.)

1.0 (ref.)

29/46

1.0 (ref.)

1.0 (ref.)

16/86

1.0 (ref.)

1.0 (ref.)

  ER+/PR-

38/85

1.1 (0.7, 1.7)

1.1 (0.7, 1.7)

9/22

0.9 (0.3, 2.3)

0.8 (0.3, 2.2)

7/4

4.9 (0.9, 26.5)

5.0 (0.9, 27.3)

8/14

4.6 (1.3, 16.4)

5.3 (1.3, 21.5)

  ER-/PR-

132/221

1.5 (1.1, 2.1)

1.2 (0.9, 1.7)

17/61

0.7 (0.3, 1.5)

0.8 (0.4, 1.6)

9/16

1.2 (0.3, 4.7)

1.2 (0.3, 4.6)

48/41

7.6 (3.0, 19.5)

8.9 (3.1, 25.9)

  Other/unknownd.e

285/556

  

45/79

  

20/61

  

29/61

  

BRCA1/2 non-carriers only, tumor status at first diagnosis

 ER status

  Positive

307/716

1.0 (ref.)

 

89/178

1.0 (ref.)

 

39/64

1.0 (ref.)

 

23/106

1.0 (ref.)

 

  Negative

137/304

1.2(0.9, 1.7)

 

19/70

0.7 (0.3, 1.5)

 

12/29

0.4 (0.1, 1.4)

 

33/52

3.6 (1.4, 8.9)

 

  Other/unknownd

152/302

  

30/42

  

9/29

  

14/32

  

 PR status

  Positive

261/593

1.0 (ref.)

 

81/159

1.0 (ref.)

 

32/59

1.0 (ref.)

 

18/88

1.0 (ref.)

 

  Negative

122/286

1.0 (0.8, 1.4)

 

21/75

0.8 (0.4, 1.7)

 

14/19

1.6 (0.5, 5.3)

 

36/52

6.7 (2.4, 18.9)

 

  Other/unknownd

213/443

  

36/56

  

14/44

  

16/50

  

 Joint ER/PR status

  ER+/PR+

233/520

1.0 (ref.)

 

77/143

1.0 (ref.)

 

27/45

1.0 (ref.)

 

15/80

1.0 (ref.)

 

  ER+/PR-

31/78

0.9 (0.5, 1.4)

 

7/22

0.7 (0.2, 2.0)

 

7/4

4.4 (0.8, 23.6)

 

6/13

3.8 (0.8, 17.2)

 

  ER-/PR-

90/197

1.2 (0.8, 1.8)

 

14/50

0.9 (0.4, 2.0)

 

7/15

0.6 (0.1, 2.8)

 

30/39

7.7 (2.6, 23.3)

 

  Other/unknownd,e

242/527

  

40/75

  

19/58

  

19/58

  
  1. Abbreviations: HR, hormone receptor, CBC contralateral breast cancer, N number, RR risk ratio, CI confidence interval, ER estrogen receptor, PR progesterone receptor. aAdjusted for age at first breast cancer diagnosis, first-degree family history of breast cancer, histologic assessment, menopausal status, age at menarche, parity, radiation, chemotherapy and hormone therapy at first breast cancer diagnosis. bAdjusted for all covariates listed in footnote a and in addition BRCA1 deleterious mutation status. c BRCA1/2 mutation status only assessed among women sampled in the first phase of the Women’s Environmental Cancer and Radiation Epidemiology Study (WECARE) I. d“Other/unknown” category consists of women for whom no laboratory test was given, the test was given and the results were unknown or the test was given and the results were borderline; estimates not reported. eIncludes tumors classified as ER-/PR+
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us